Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients

Blood

Volumn 117, Issue 11, 2011, Pages 3025-3031

  Gay, Francesca ^a   Larocca, Alessandra ^a   Wijermans, Pierre ^b   Cavallo, Federica ^a   Rossi, Davide ^c   Schaafsma, Ron ^d   Genuardi, Mariella ^a   Romano, Alessandra ^e   Liberati, Anna Marina ^f   Siniscalchi, Agostina ^g   Petrucci, Maria T ^h   Nozzoli, Chiara ⁱ   Patriarca, Francesca ^j   Offidani, Massimo ^k   Ria, Roberto ^l   Omedè, Paola ^a   Bruno, Benedetto ^a   Passera, Roberto ^a   Musto, Pellegrino ^m   Boccadoro, Mario ^a   Sonneveld, Pieter ⁿ   Palumbo, Antonio ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b HAGA HOSPITAL   (Netherlands)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF PERUGIA   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j UNIVERSITY HOSPITAL OF UDINE   (Italy)

^k OSPEDALI RIUNITI   (Italy)

^l UNIVERSITY OF BARI   (Italy)

^m REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; M PROTEIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79953078844     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307645     Document Type: Article

References (32)

1. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
2. Ailawadhi S, Sher T, Patel M, et al. International Staging System (ISS) is superior to Durie-Salmon (DS) staging in predicting overall mortality in multiple myeloma (MM). Blood. 2008;112. Abstract 948.
3. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
4. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005; 23(26):6339-6344. (Pubitemid 46218844)
5. Hoering A, Crowley J, Shaughnessey JD, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood. 2009;114(7):1299-1305.
6. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with long survival with longer survival. J Clin Oncol. 2008;26(35):5775-5782.
7. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol. 2009; 27(34):5720-5726.
8. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367(9513):825-831. (Pubitemid 43363369)
9. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet. 2007;370(9594):1209-1218. (Pubitemid 47516593)
10. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-3670.
11. Waage A, Palumbo A, Fayers P, et al. MP versus MPT for previously untreated elderly patients with multiple myeloma: a meta-analysis of 1682 individual patient data from six randomized clinical trials. J Clin Oncol. 2010;28. Abstract 8130.
12. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19): 3160-3166.
13. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008; 112(8):3107-3114.
14. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
15. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010; 28(13):2259-2266.
16. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib- melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide versus bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomised controlled trial. J Clin Oncol. 2010; 28(34):5101-5109.
17. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
18. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473. (Pubitemid 44264086)
19. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1): 3-9.
20. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol. 1998;16(12):3832-3842.
21. Kyle RA, Leong T, Li S, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer. 2006; 106(9):1958-1966. (Pubitemid 43673211)
22. Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalanprednisone. Blood. 2010;116(19):3743-3750.
23. Van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progressionfree survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92(10):1399-1406. (Pubitemid 350144158)
24. Jacobus S, Callander N, Siegel D, et al. Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG Randomized Trial of Lenalidomide/High-Dose Dexamethasone (RD) Versus Lenalidomide/Low-Dose Dexamethasone (Rd). Haematologica. 2010;95:149. Abstract 370.
25. Ludwig H, Hajek R, Tóthová E, et al. Thalidomide- dexamethasone compared with melphalan-prednisone in elderly patients with multiple myeloma. Blood. 2009;113(15):3435-3442.
26. Facon T, Mary JY, Pégourie B, et al. Dexamethasone- based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107(4): 1292-1298. (Pubitemid 43242361)
27. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
28. Harousseau JL, Dimopoulus M, Wang M, et al. Better quality of response to Lenalidomide plus Dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Hematologica. 2010; 95(10):1738-1744.
29. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12): 2077-2084.
30. San Miguel JF, Almeida J, Mateo G, et al: Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99(5):1853-1856. (Pubitemid 34533063)
31. Attal M, Cristini C, Marit G, et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol. 2010;28:15s. Abstract 8018.
32. McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM):CALGB 100104. J Clin Oncol. 2010;28:15s. Abstract 8017.